GlassScriptPhysician profile
Laura A Pecorella
NPI 1467435453
$8,369.63
in general payments reported to CMS, 2019-2025
46 companies · $2,258 in 2025
The $2,258 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,381 · 2022: $1,584 · 2023: $1,612 · 2024: $1,535 · 2025: $2,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,318 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,317.66 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,312.15 | 2023-2025 | |
| Abbvie INC. | $973.48 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $857.46 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $480.65 | 2021-2025 | Reyvow, Emgality, Kisunla |
| Otsuka America Pharmaceutical, INC. | $329.01 | 2023-2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $302.21 | 2021-2025 | Crexont, Rytary, Ongentys |
| Ucb, INC. | $268.35 | 2021-2025 | Rystiggo, Nayzilam, Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $266.92 | 2022 | |
| Lundbeck LLC | $249.49 | 2021-2025 | Vyepti, Rexulti |
| Biogen, INC. | $215.77 | 2022-2024 | Vumerity, Avonex, Tysabri |
| Sk Life Science, INC. | $213.90 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $210.05 | 2021-2023 | Ongentys, Ingrezza |
| Acadia Pharmaceuticals INC | $206.48 | 2021-2025 | Nuplazid |
| Mallinckrodt Hospital Products INC. | $195.13 | 2024-2025 | Acthar |
| Amgen INC. | $164.87 | 2021-2025 | Uplizna |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $148.51 | 2021-2025 | Gocovri |
| Neurelis, INC. | $146.81 | 2022-2023 | Valtoco |
| Upsher-Smith Laboratories LLC | $146.42 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $132.31 | 2021-2022 | |
| Acorda Therapeutics, INC | $126.86 | 2021-2023 | Inbrija, Ampyra |
| Biohaven Pharmaceuticals, INC. | $115.54 | 2021 | |
| Medtronic, INC. | $109.04 | 2025 | Percept PC Brainsense |
| Astrazeneca Pharmaceuticals LP | $106.45 | 2022-2025 | Wainua |
| Jazz Pharmaceuticals INC. | $103.76 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $96.56 | 2021-2025 | Qelbree |
| Eisai INC. | $94.84 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $90.56 | 2023 | Trudhesa |
| Abbott Laboratories | $82.47 | 2023-2024 | Infinity |
| Livanova USA, INC. | $81.88 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Kyowa Kirin, INC. | $68.25 | 2021-2022 | |
| Incyte Corporation | $60.99 | 2021 | |
| Axsome Therapeutics, INC. | $52.37 | 2025 | Symbravo, Auvelity |
| Alexion Pharmaceuticals, INC. | $47.26 | 2024-2025 | Ultomiris |
| Allergan, INC. | $39.95 | 2021 | |
| Xeris Pharmaceuticals, INC. | $34.19 | 2022 | |
| Argenx US, INC. | $33.46 | 2022-2023 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $29.81 | 2024 | |
| Janssen Biotech, INC. | $29.17 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.94 | 2021 | |
| Tonix Medicines, INC. | $23.46 | 2024 | Zembrace Symtouch |
| Averitas Pharma INC. | $20.39 | 2025 | Qutenza |
| Ani Pharmaceuticals, INC. | $16.63 | 2022 | |
| Banner Life Sciences, LLC | $16.23 | 2022 | |
| Celgene Corporation | $15.21 | 2022 | |
| Emd Serono, INC. | $15.07 | 2022 | |
| Genzyme Corporation | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Pecorella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.